Artis BioSolutions to acquire Syngoi Technologies,

Artis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, agreed to acquire Syngoi Technologies, a Spanish biotechnology company focused on synthetic DNA technologies for use in advanced therapies. Financial terms are not disclosed. “Joining Artis marks an important next chapter for Syngoi. Artis shares our long-term vision, and together with Landmark Bio, this partnership significantly enhances our ability to deliver differentiated synthetic DNA solutions at a global scale. It strengthens our value proposition for customers and partners seeking reliable, high-quality platforms for advanced therapies," José Vicente Pons Andreu, Syngoi CEO.